Aurobindo Pharma Limited
AUROPHARMA
Rank in Stocks
#2074
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures,... Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Share Price
$17.34
Last synced: 2026-10-21
Market Cap
$9.98B
Change (1 day)
-3.08%
Change (1 year)
38.71%
Country
IN
Trade Aurobindo Pharma Limited (AUROPHARMA)
Category
Healthcare
Revenue for Aurobindo Pharma Limited (AUROPHARMA)
Revenue in Jun 2026 TTM: $3.85B
According to Aurobindo Pharma Limited latest financial reports the company's current revenue (TTM) is $3.85B. In 2024 the company made a revenue of $3.48B an increase over the revenue in the year 2023 that was $3.02B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Aurobindo Pharma Limited from 2004 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $3.85B | 3.81% |
| 2025 | $3.71B | 6.64% |
| 2024 | $3.48B | 15.00% |
| 2023 | $3.02B | -2.12% |
| 2022 | $3.09B | -8.70% |
| 2021 | $3.38B | 10.38% |
| 2020 | $3.07B | 8.83% |
| 2019 | $2.82B | 11.42% |
| 2018 | $2.53B | 9.80% |
| 2017 | $2.30B | 10.42% |
| 2016 | $2.09B | 7.24% |
| 2015 | $1.94B | -3.94% |
| 2014 | $2.02B | 87.34% |
| 2013 | $1.08B | 20.74% |
| 2012 | $894.99M | -8.97% |
| 2011 | $983.16M | 23.50% |
| 2010 | $796.09M | 31.34% |
| 2009 | $606.15M | -0.42% |
| 2008 | $608.73M | 24.30% |
| 2007 | $489.74M | 36.87% |
| 2006 | $357.80M | 18.22% |
| 2005 | $302.66M | -12.68% |
| 2004 | $346.60M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 71.71% |
IN
|
